Balance Sheet Components (Tables)

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of reconciliation of total cash, cash equivalents and restricted cash

The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash as of March 31, 2022 and December 31, 2021, respectively, in the condensed consolidated statements of cash flows:

	March 31, 2022		December 31, 2021
Cash and cash equivalents	$	169,065	$	171,945
Restricted cash (included in other current assets)	4,559		1,648
Restricted cash (included in other assets)	750		750
Cash, cash equivalents and restricted cash in the statements of cash flows	$	174,374	$	174,343

Schedule of inventories

Inventory consisted of the following:

	As of March 31, 2022		As of December 31, 2021
Work-in-process	169,390		159,075
Finished goods	13,731		9,269
Total inventories	$	183,121	$	168,344
Less noncurrent inventories(1)	91,840		87,736
Total inventories classified as current	$	91,281	$	80,608

(1) Included in other assets on the condensed consolidated balance sheets. There are no recoverability issues for these amounts.

Schedule of prepaid expenses

Prepaid expenses consisted of the following:

	As of March 31, 2022		As of December 31, 2021
Prepaid clinical trial costs	$	58,562	$	42,578
Prepaid manufacturing	8,856		17,448
Prepaid commercial costs	33,248		15,732
Other prepaid expenses	4,225		13,080
Prepaid expenses	$	104,891	$	88,838

Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following:

	As of March 31, 2022		As of December 31, 2021
Accrued development milestones	$	5,000	$	5,000
Accrued employee compensation and benefits	35,362		40,109
Accrued clinical trial costs	36,051		37,477
Accrued commercialization and other professional fees	22,744		19,994
Accrued sales discounts and allowances	233,096		203,760
Current obligation to perform R&D services	29,642		22,030
Other accrued expenses and other current liabilities	95,517		91,649
Accrued expenses and other current liabilities	$	457,412	$	420,019